Publication: Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma. Is Chemotherapy a Factor?
Issued Date
2007-07-01
Resource Type
ISSN
01616420
Other identifier(s)
2-s2.0-34347342867
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Ophthalmology. Vol.114, No.7 (2007), 1378-1383
Suggested Citation
Dan S. Gombos, John Hungerford, David H. Abramson, Judith Kingston, Guillermo Chantada, Ira J. Dunkel, Celia B.G. Antoneli, Mark Greenwald, Barret G. Haik, Carlos A. Leal, Aurora Medina-Sanson, Amy C. Schefler, Gavivann Veerakul, Regina Wieland, Norbert Bornfeld, Mathew W. Wilson, Christopher Bing On Yu Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma. Is Chemotherapy a Factor?. Ophthalmology. Vol.114, No.7 (2007), 1378-1383. doi:10.1016/j.ophtha.2007.03.074 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/24841
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma. Is Chemotherapy a Factor?
Other Contributor(s)
University of Texas MD Anderson Cancer Center
Barts and The London NHS Trust
Moorfields Eye Hospital NHS Foundation Trust
Memorial Sloan-Kettering Cancer Center
Hospital JP Garrhan
Hospital Sao Paulo
University of Chicago
University of Tennessee Health Science Center
Instituto Nacional de Pediatria
Hospital Infantil de Mexico Federico Gomez
University of Miami Leonard M. Miller School of Medicine
Mahidol University
Universitat Duisburg-Essen
Chinese University of Hong Kong
Barts and The London NHS Trust
Moorfields Eye Hospital NHS Foundation Trust
Memorial Sloan-Kettering Cancer Center
Hospital JP Garrhan
Hospital Sao Paulo
University of Chicago
University of Tennessee Health Science Center
Instituto Nacional de Pediatria
Hospital Infantil de Mexico Federico Gomez
University of Miami Leonard M. Miller School of Medicine
Mahidol University
Universitat Duisburg-Essen
Chinese University of Hong Kong
Abstract
Purpose: To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB). Design: Retrospective observational cases series. Participants: Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center. Methods: Physician survey, retrospective database review, and literature search. Main Outcome Measures: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead). Results: Fifteen patients with sAML were identified; 13 occurred in childhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79 %) had received chemotherapy with a topoisomerase II inhibitor, 8 (43%) had received chemotherapy with an epipodophyllotoxin. Ten children died of their leukemia. Conclusions: Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort. © 2007 American Academy of Ophthalmology.